Viridian Therapeutics, Inc. VRDN 深 滬
已收盤 04-02 16:00:00 美东时间
18.84
-0.310
-1.62%
華盛通- 最 高19.245
- 今 開18.56
- 成交量 305.63万股
- 最 低 18.44
- 昨 收 19.15
- 總市值 19.26亿
- 52周最高 34.29
- 市盈率 靜 --
- 換手率 2.99%
- 52周最低 11.76
- 委 比 28.57%
- 總股本 1.02亿
- 歷史最高 270.00
- 量 比 0.65
- 振 幅 4.20%
- 歷史最低 4.665
- 每 手 1
- 風險率 7.14%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股周涨跌榜 | 药企并购潮来袭！Apellis制药飙升138%，获生化基因公司高额溢价收购；CNTA周涨38%
药企并购潮来袭！Apellis制药飙升138%，获高额溢价收购；SpaceX已递交上市申请！FLY周涨38%，公司为NASA新一代登月火箭供应商；CNTA周涨38%，公司获礼来收购>>
04-03 11:11
美股大行评级 | 存储分歧大！花旗大砍17%将美光目标价从510降至425美元；Bernstein上调希捷科技目标价从500升至620美元
今日重点评级关注：Maxim Group：上调Theriva Biologics评级至"买入"，目标价1美元；HC Wainwright & Co.：维持Bicara Therapeutics"买入"评级，目标价从40美元升至42美元
04-01 16:34
美股大行评级 | 潜在涨幅172.14%！Alumis获Oppenheimer上调目标价至55美元；摩根大通首予希捷科技"超配"评级，目标价525美元
今日重点评级关注：Oppenheimer：维持Alumis"跑赢大市"评级，目标价从50美元升至55美元；美银证券：维持Rocket Pharmaceuticals"买入"评级，目标价从8美元升至9美元
03-31 16:30
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks
U.S. RESEARCH ROUNDUP-Dutch Bros, Phreesia, Starbucks March 31 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Dutch Bros, Phreesia and Starbucks on Tuesday. HIGHLIGHTS * Dutch Bros Inc BROS.N : Exane BNP Paribas initiat
03-31 15:39
Why Is Viridian Therapeutics Stock Falling Monday?
Viridian (VRDN) shares plunge 38% premarket despite positive Phase 3 TED trial data. Analysts weigh in on elegrobart's market viability.
03-30 22:01
UPDATE 1-Viridian's thyroid eye disease drug succeeds in late-stage trial
UPDATE 1-Viridian's thyroid eye disease drug succeeds in late-stage trial Adds details throughout March 30 (Reuters) - Viridian Therapeutics VRDN.O said on Monday its experimental drug met the main goal in late-stage study, when tested in patients with active thyroid eye disease. The injectable drug
03-30 19:17
Viridian Therapeutics Says REVEAL-1 Study Met Primary Endpoint Of Every Four Weeks (Q4W) Proptosis Responder Rate In Thyroid Eye Disease
REVEAL-1 met the primary endpoint of Q4W proptosis responder rate (PRR) with a highly statistically significant treatment effect.Elegrobart Q4W and Q8W achieved clinically meaningful 54% and 63% PRR versus 18% placebo at
03-30 19:16
Viridian's thyroid eye disease drug succeeds in late‑stage trial
Viridian's thyroid eye disease drug succeeds in late‑stage trial March 30 (Reuters) - Viridian Therapeutics VRDN.O said on Monday its experimental drug met the main goal when tested in patients with active thyroid eye disease in late-stage study. (Reporting by Siddhi Mahatole in Bengaluru; Editing b
03-30 19:07
Viridian says elegrobart hits primary endpoint in Phase 3 REVEAL-1 thyroid eye disease trial
Viridian says elegrobart hits primary endpoint in Phase 3 REVEAL-1 thyroid eye disease trial Viridian reported positive topline results from Phase 3 REVEAL-1 trial of subcutaneous elegrobart in active thyroid eye disease; results were presented in announcement. Trial met primary endpoint at week 24,
03-30 19:06
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan
U.S. RESEARCH ROUNDUP- Ferguson Enterprises, Hartford Insurance Group, JP Morgan March 30 (Reuters) - Wall Street securities analysts revised their ratings and price targets on several U.S.-listed companies, including Ferguson Enterprises, Hartford Insurance Group and JP Morgan, on Monday. HIGHLIGHT
03-30 15:35
